Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of premorbid nutritional status on TB severity.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2025
Same author

Efficacy of neuromuscular exercises to promote movement quality and reduce musculoskeletal injury during initial military training in Royal Navy recruits.

BMJ military health·2024
Same author

Antidepressant Exposure and DNA Methylation: Insights from a Methylome-Wide Association Study.

medRxiv : the preprint server for health sciences·2024
Same author

Achievement of Target Gain Larger than Unity in an Inertial Fusion Experiment.

Physical review letters·2024
Same author

Impact of the COVID-19 Pandemic on Outcomes for Patients with Lung Cancer Receiving Curative-intent Radiotherapy in the UK.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

Observation versus intervention for incidental common bile duct stones at intraoperative cholangiogram: a systematic review.

ANZ journal of surgery·2023
Same journal

Lifting the Lid on Best Practice in a Case of Oligometastatic Breast Cancer.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Standardisation of Imaging Surveillance for Patients With Metastatic Melanoma Stopping Immune Checkpoint Inhibitors.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Valuing Public Sector Data Assets: Methodological Perspectives From the Add-Aspirin Trial's Use of Healthcare Systems Data for Clinical Follow-Up.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Autologous Cell Therapy in Oncology: Current Landscape and Future Directions.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Proton Beam Therapy for Intracranial Germ Cell Tumors in Pediatric, Adolescent, and Young Adult Patients: A Single-Center Experience.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same journal

Patient Perspectives on Reirradiation for Recurrent Cancer, to Inform Future Clinical Trial Design.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
See all related articles

Related Experiment Video

Updated: Aug 29, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Implementing Genomic Testing for Lung Cancer Into Routine Clinical Practice - The Welsh Experience.

S Cox1, C Powell1, S Morgan2

  • 1Velindre Cancer Centre, Velindre University NHS Trust, Cardiff, UK.

Clinical Oncology (Royal College of Radiologists (Great Britain))
|September 10, 2022
PubMed
Summary
This summary is machine-generated.

Wales established a national biomarker testing pathway for non-small cell lung cancer (NSCLC), improving genomic testing standards. Challenges in tissue quality and turnaround times require further optimization for better patient outcomes.

Keywords:
BiomarkerNSCLCdriver mutationgenomic testinglung cancerprecision medicine

More Related Videos

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
11:20

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

11.0K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.4K

Related Experiment Videos

Last Updated: Aug 29, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K
Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
11:20

Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology

Published on: March 21, 2018

11.0K
A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.4K

Area of Science:

  • Oncology
  • Genomics
  • Molecular Diagnostics

Background:

  • Non-small cell lung cancer (NSCLC) has seen rapid advancements in identifying actionable driver mutations.
  • Numerous targeted therapies are now available for NSCLC patients with specific genetic alterations.

Purpose of the Study:

  • To summarize the implementation of a national biomarker testing pathway for NSCLC in Wales.
  • To embed this pathway within the National Optimal Pathway for Lung Cancer.

Main Methods:

  • A working group was established by the Welsh Thoracic Oncology Group to standardize genomic testing.
  • A national survey of multidisciplinary teams (MDTs) and a retrospective audit of the next-generation sequencing (NGS) pathway were conducted.

Main Results:

  • Seventy percent of MDTs participated in the survey, revealing variability in testing practices.
  • 87% of MDTs adopted DNA and RNA NGS as standard care, with a median turnaround time of 25-26 days.
  • Pathology-initiated reflex testing was associated with shorter biopsy-to-result times.

Conclusions:

  • Significant progress has been made in establishing a national NSCLC biomarker testing pathway in Wales.
  • Challenges persist in optimizing tissue quality and reducing turnaround times for genomic testing.
  • Further improvements are needed to ensure timely and comprehensive testing for optimal treatment selection and patient outcomes.